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PL-001 USP18 stimulates HCV production and blunts
the antiviral effect of IFNa independent of its
protease activity
L. Chen1 *, J. Sun1, J. Heathcote1, A. Edwards1,
I. McGilvray1. 1University of Toronto, Canada
Background: Combination therapy with pegylated
Interferon and Ribavirin is the best treatment for patients
infected with hepatitis C virus (HCV), but it is only effective
in half of patients. We recently demonstrated that USP18,
the ISG15-speciﬁc protease, is important to HCV responses:
it is one of the 18 gene signature predictive of response
to therapy (Chen et al Gastroenterology 2005, 2010), and
knockdown of USP18 increases the anti-HCV effect of IFNa
(Randall et al Gastroenterology 2006). In this study we
investigated how USP18 protease activity modulates HCV
replication with and without IFNa.
Methods: USP18 wild type (wt) and a protease-inactive
mutant (USP18 C64S, mUSP18) expression constructs were
cloned with an N-terminal GFP tag. Enzymatic activity
of the expressed USP18 was conﬁrmed by co-transfecting
wtUSP18 or mUSP18 with plasmid DNA expressing ISG15-GST
fusion protein. The effect of over-expression of wtUSP18
or mUSP18 on HCVRNA replication/viral particle secretion
with or without IFNa was tested in the J6/JFH1 infectious
culture system.
Results: Over-expression of wtUSP18 in Huh7.5 cells led
to decreased ISGylation in the presence of IFNa, an effect
not seen with overexpression of mUSP18. Overexpression
of both wtUSP18 and mUSP18 increased baseline HCVRNA
replication and production of infectious virus by 4 5 fold;
overexpression of both also blunted the anti-HCV effect of
IFNa. Neither wtUSP18 nor mUSP18 inhibited the expression
of common ISGs (MxA, ISG15, OAS2, Viperin) after exposure
of Huh7.5 cells to IFNa.
Conclusions: USP18 modulates HCV replication and the anti-
HCV activity of IFNa independent of its protease activity
and without disrupting IFNa signaling. These studies reveal
that increased USP18 expression may be one way that
HCV shelters itself from the host response, and should be
considered a target for new anti-HCV therapies.
OL-001 Association study of genetic variation in IL28B
with the hepatitis C treatment-induced viral
clearance in Chinese Han population
X.W. Liao1 *, Y. Ling1, X.H. Li1, Y. Han1, S.Y. Zhang1,
L.L. Gu1, D.M. Yu1, B.L. Yao1, D.H. Zhang1, G.D. Jin1,
Z.M. Lu1, Q.M. Gong1, X.X. Zhang1. 1Department of
Infectious Diseases, Ruijin Hospital, Shanghai Jiaotong
University, School of Medicine, China
Background: Genome-wide association studies have
recently conﬁrmed the rs12979860 variation in IL28B is
associated with the response to chronic hepatitis C (HCV)
treatment. The aim of this study is to investigate whether
the rs12979860 variation could be used as a predictive
marker for end-of-treatment response (ETR) or sustained
virological response (SVR) in Chinese Han population.
Methods: Totally, 259 HCV infected individuals were
detected the rs12979860 genotypes by DNA sequencing.
Among them, 120 patients with complete pegylated
interferon Alfa and ribavirin combination therapy and 92
patients followed for 24 weeks after the cessation of
treatment were divided into different groups according to
outcomes of treatment.
Results: The rs12979860 CC genotype was the main
genotype in Chinese Han patients (87.64%, 227/259) and
only one TT genotype was found in this cohort of patients.
The patients with rs12979860 CC genotype got higher rates
of ETR (P= 0.0044) and SVR (P= 0.0046) than the patients
with N-CC (CT, TT) genotypes. In multiple logistic-regression
models, the rs12979860 variation was associated with a
more substantial difference in rates of achieving ETR (OR:
8.983, CI: 2.173 37.145, P= 0.0024) and SVR (OR: 24.298, CI:
2.272 259.901, P= 0.0083) than the other factors, including
sex, age, HCV genotypes and baseline viral load.
Conclusion: This study demonstrated that the rs12979860
variation in IL28B could be as a predictor for ETR and SVR
in Chinese Han patients with HCV infection.
OL-002 Effect of high-dose ribavirin (RBV), Alinia
(Nitazoxanide) and pegylated interferon
(PegIFN) alfa-2a in attaining sustained virologic
response (SVR) in treatment of chronic
hepatitis C (ERAIS-C Trial) in naı¨ve genotype 1
patients
P.P. Basu1 *, K. Rayapudi2, T. Pacana2, N.J. Shah2,
N. Krishnaswamy2, H. Hampole2, C. Tang2, R. Brown1.
1Columbia University College of Physicians & Surgeons,
New York, NY, USA, 2 Forest Hills Hospital, Forest Hills,
New York, USA
Purpose: PegIFN and Ribavirin (RBV) remain the backbone
of therapy of chronic hepatitis C and achieve a
sustained virologic response (SVR) rate of ~50% globally
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in all genotypes (~30% in African Americans). Alinia
(nitazoxanide[NTZ]), an interferon inducer may increase
SVR in combination with PegIFN and RBV. Very rapid virologic
response (VRVR) deﬁned as undetectable HCVRNA 14 days
after initiation of combination therapy may predict even
higher SVR rates. We assessed NTZ in combination with
high-dose RBV and PegIFN alfa-2a in Hepatitis C treatment.
Methods: Prospective, open-label, pilot study of naı¨ve
patients with chronic hepatitis C GT1. 33 patients
were enrolled. Exclusions: uncontrolled diabetes mellitus,
decompensated cirrhosis etc. Patients received NTZ 500mg
bid for ﬁrst 2 weeks; RBV 800mg in AM and 600mg at night
added to NTZ for next 2 weeks; subcutaneous PegIFN alfa-2a
180mcg weekly added to RBV and NTZ at the same dose
(triple-regimen) for next 12 weeks. Patients who achieved
EVR continued PegIFN alfa-2a and RBV for the next 36 weeks
at the same dose. VRVR, Rapid Viral Response (RVR), Early
Viral response (EVR), End Treament Viral Response (ETR),
and Sustained Viral Response (SVR) were assessed (COBAS
TaqMan HCV Test v2.0, Roche Diagnostics).
Results: Overall SVR 66.7% (22/33). Demographics:
Caucasian (n = 16, 48.5%), Hispanic (n = 6, 18.2%), African-
American (n = 5, 15.1%), and Asian (n = 6, 18.2%). Mean
BMI 27.9; mean HCVRNA-600,000 IU/ml; ﬁbrosis score-
F2 (48.5%). Growth factors were used to minimize
dose reductions. Adverse effects (AE): skin rash (27.3%);
neutropenia (51.5%); thrombocytopenia (39.4%); anemia
(48.5%); 6.1% discontinued treatment due to AE. None had
dose reductions.
Conclusion: This regimen of NTZ, high-dose RBV and PegIFN
alfa-2a enhances RVR over historical controls and offers an
improved SVR rate of 66.7% compared to 40.9% SVR rate in
GT1 from the recent IDEAL Study.
OL-003 The clinical features in HIV/AIDS complicated
with cytomegalovirus infection
J. Xiao1, N. Han1, H.-Y. He1, L.-H. Wang1, G.-J. Gao1,
H.-Y. Liang1, D. Yang1, L.-Y. Zhang1, H.-X. Zhao1 *. 1Division
1 of Department of Infectious Diseases, China
To promote the diagnostic rate of HIV/AIDS complicated with
cytomegalovirus (CMV) viremia, enhance curative effects
and improve the prognosis. The clinical data in 249 cases of
HIV/AIDS patients hospitalized from Oct.2008 to Nov. 2009
have been collected and studied retrospectively, in which
we found that 43 HIV/AIDS patients have infected CMV.
Pathological detections have been analyzed from specimen
taken with gastroscope, ﬁbercoloscope, bronchoscope and
bronchoalveolar lavage ﬂuid (BALF). We also analyzed
association between cellular immunity and CMV-DNA levels.
We found that 43 patients (17.3%) have been diagnosed
as CMV viremia in accordance with positive results of
CMV pp65 antigen and CMV-DNA; 14 patients manifested
Figure 1. Retinitis.
Figure 2. CMV pneumonitis.
retinal bleeding or inﬁltration and 4 patients displayed
retinal ﬁbrosis; 1 patients have been diagnosed as CMV
pneumonitis according to pathological results from BALF;
No CMV esophagitis or colitis has been diagnosed in
these 43 patients. We also found the positive association
between low level of CD4+T lymphocytes and CMV-DNA
levels. The detections of CMV pp65 antigen and CMV-
DNA should be detected and anti-CMV treatment should
be taken in HIV/AIDS patients with less than 50/ul
of CD4+T lymphocytes. Ophthalmologic examination and
pathological detection in BALF are effective methods in
diagnosing CMV retinitis and pneumonitis.
OL-004 HIV-1 genotyping of protease and
reverse-transcriptase mutation resistances in
Kelantan, Malaysia
Z.Z. Deris1, S. Mohamad1 *, T.M. Akram, T.M. Arifﬁn1,
M. Mustafa2, N.K. Yusof2, C.B. Chew3. 1Medical
Microbiology & Parasitology, Universiti Sains Malaysia,
Malaysia, 2Hospital Raja Perempuan Zainab 2, Kelantan,
Malaysia, 3Centre for Infectious Diseases and Microbiology
Laboratory Services, Australia
Background: HIV-1 genotypic-resistance is becoming
increasingly signiﬁcant in drug resistance monitoring.
However, many areas in some developing countries in Asia
still lack of such information due to its high running cost.
This is the ﬁrst study to determine the prevalence of
drug resistance mutations of reverse transcriptase (RT) and
protease (PR) genes and speciﬁc HIV-1 subtypes in North-
eastern part of Malaysia.
Methods: The genotypic resistance testing was performed
among 50 HIV-1 seropositive treated and treatment naı¨ve
subjects in Hospital Raja Perempuan Zainab 2, Kota Bharu.
The HIV-1 PR and RT genes were ampliﬁed from 140ml of
plasma-derived HIV-1 viral RNA via reverse transcription-
polymerase chain reaction and genotype determined via
DNA sequencing. Drug resistance mutations were analysed
using the Stanford HIV Sequence Resistance Database.
Results: CRF01_AE was found to be the dominant subtype
by both PR and RT genes in both antiretroviral treated and
naive patients (59.4%). B subtype was present to a much
lower level (21.9%), followed by CRF01_AE/B intersubtype
recombinant (18.8%). Fifteen percent of the treated and
0.06% naı¨ve patients had mutations associated with PIs.
The frequency of mutations associated with NRTIs and
NNRTIs resistance in treated patients was 40.6% and 34.4%,
respectively compared to 0.06% and 0.09% in naı¨ve patients.
